Diphtheria toxin CRM197

更新时间：2025-08-26 06:56:00

Diphtheria toxin CRM197结构式	常用名	Diphtheria toxin CRM197	英文名	Diphtheria toxin CRM197
	CAS号	92092-36-9	分子量	N/A
	密度	N/A	沸点	N/A
	分子式	N/A	熔点	N/A
	MSDS	美版	闪点	N/A
	符号	GHS06	信号词	Danger

Diphtheria toxin CRM197用途

Diphtheria toxin CRM197 是白喉毒素的一个无毒变种,具有一个单一的突变 (52 位的甘氨酸到谷氨酸的替代),可以消除其毒性。CRM197 作为载体蛋白广泛应用于疫苗中。

中文名	白喉毒素,CRM突变体
英文名	DIPHTHERIA TOXIN

描述	Diphtheria toxin CRM197 是白喉毒素的一个无毒变种,具有一个单一的突变 (52 位的甘氨酸到谷氨酸的替代),可以消除其毒性。CRM197 作为载体蛋白广泛应用于疫苗中。
相关类别	研究领域 >> 感染信号通路 >> 其他 >> 其他
体外研究	白喉毒素CRM197是一种酶活性低、无毒的白喉毒素,含有单一氨基酸替代物(G52E)。由于天然无毒,CRM197是一种理想的载体蛋白,可用于结合疫苗对抗包膜细菌,目前用于全球儿童接种流感嗜血杆菌、肺炎球菌和脑膜炎球菌[1][2]。白喉毒素是一种由白喉棒状杆菌裂解株分泌的单一多肽,通过进入细胞胞浆并抑制蛋白质合成而引起人类白喉疾病[3][4]。
参考文献	[1]. Ravi P N Mishra, et al. Structural and Immunological Characterization of E. coli Derived Recombinant CRM 197 Protein Used as Carrier in Conjugate Vaccines. Biosci Rep. 2018 Sep 25;38(5):BSR20180238. [2]. Enrico Malito, et al. Structural Basis for Lack of Toxicity of the Diphtheria Toxin Mutant CRM197. Proc Natl Acad Sci U S A. 2012 Apr 3;109(14):5229-34. [3]. C E Bell, et al. Crystal Structure of Diphtheria Toxin Bound to Nicotinamide Adenine Dinucleotide. Biochemistry. 1996 Jan 30;35(4):1137-49. [4]. Ranjit Sah, et al. Diphtheria. N Engl J Med. 2019 Sep 26;381(13):1267.

InChIKey	OMKSMMMRXPURJL-GYTVPHJMSA-O
SMILES	CCC=CCC=CCC=CCC=CCC=CCCCC(=O)OCC(C)(C)C(OC(=O)c1ccccc1OC(=O)c1ccccc1OC(C)=O)C(=O)NC(N)(CC(=O)O)C(N)=NC(N)=[N+](C)C
外观性状	lyophilized powder
储存条件	2-8°C

符号	GHS06
信号词	Danger
危害声明	H300
警示性声明	Missing Phrase - N15.00950417
个人防护装备	Eyeshields;Gloves;type N95 (US);type P1 (EN143) respirator filter
危害码 (欧洲)	T+
风险声明 (欧洲)	28
安全声明 (欧洲)	22-24/25-45-36/37-28
危险品运输编码	3172
WGK德国	3
RTECS号	XW5807200
包装等级	I
危险类别	6.1(a)

Carbohydrate-based vaccines with a glycolipid adjuvant for breast cancer.

Proc. Natl. Acad. Sci. U. S. A. 110(7) , 2517-22, (2013)

Globo H (GH) is a hexasaccharide specifically overexpressed on a variety of cancer cells and therefore, a good candidate for cancer vaccine development. To identify the optimal carrier and adjuvant co...

Glycoconjugate vaccines and immune interactions, and implications for vaccination schedules.

Expert Rev. Vaccines 10(11) , 1621-31, (2011)

Conjugate vaccines using diphtheria toxoid variant (CRM(197)), diphtheria toxoid and tetanus toxoid (TT) as carrier protein may induce immune interactions (interference or impairment as measured by lo...

Antitumor effects of CRM197, a specific inhibitor of HB-EGF, in T-cell acute lymphoblastic leukemia.

Anticancer Res. 31(7) , 2483-8, (2011)

The therapeutic outcome for T-cell acute lymphoblastic leukemia (T-ALL) remains poor; thus, novel, targeted therapies are urgently needed. Recently, we showed that heparin-binding epidermal growth fac...